The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...
GAINESVILLE, FL - March 09, 2026 - PRESSADVANTAGE - Awaken Chiropractic operates as a chiropractic practice in ...
News-Medical.Net on MSN
Microbial ecosystems influence success of cancer checkpoint immunotherapy
Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results